Meeting
2023 ASCO Annual Meeting
Final results of a pilot study of docetaxel and carboplatin for treatment of patients with mCRPC containing biallelic inactivation of genes in the homologous recombination DNA repair pathway.
Authors
Ruben Raychaudhuri
Fred Hutchinson Cancer Center, Seattle, WA
Ruben Raychaudhuri , Makayla DeJong , Evan Y. Yu , Roman Gulati , Matthew Rettig , Peter Nelson , Colin C. Pritchard , Robert Bruce Montgomery , Heather H. Cheng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Castrate-Resistant
Clinical Trial Registration Number
NCT02598895
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5054)
DOI
10.1200/JCO.2023.41.16_suppl.5054
Abstract #
5054
Poster Bd #
148
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
A pilot study of docetaxel and carboplatin for treatment of patients with mCRPC containing biallelic inactivation of genes in the BRCA1/2 pathway.
First Author: Heather H. Cheng
Poster
2022 ASCO Annual Meeting
Detection of homologous recombination deficiency (HRD) in cell-free DNA (cfDNA) using an amplicon-based next-generation sequencing (NGS) assay.
First Author: Jonathan Poh
Poster
2020 Gastrointestinal Cancers Symposium
Homologous recombination deficiency (HRD) by BROCA-HR and survival outcomes after surgery for patients (pts) with pancreatic adenocarcinoma (PC): A single institution experience.
First Author: Amy E. Chang
Poster
2018 ASCO Annual Meeting
Treatment outcomes for patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) pts and DNA damage repair gene mutations.
First Author: Steven Yip